Mirati Therapeutics, Inc. MRTX
Set alert
58.70 +58.70 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 4.12B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -7.01
- Beta
- 0.77
- Short ratio
- 2.88
- Inst. own
- 117.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 27, 2024
- 50-d avg
- 57.93
- 200-d avg
- 45.92
- 1y target
- 64.50
Analyst view
Consensus: hold
Hold
Price target (mean) 64.50 +9.9% upside
Now 58.70
- Target (low)
- 58.00
- Target (mean)
- 64.50
- Target (high)
- 82.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy3
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 17
- 2 months ago 17
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -2.43 | -2.68 – -2.16 | -3.51 | +30.8% | 22.09M | +2265.1% | 4 |
| Next quarter | -2.46 | -2.69 – -2.23 | -3.18 | +22.6% | 21.90M | +205.6% | 2 |
| Current year | -10.99 | -11.39 – -10.54 | -13.18 | +16.6% | 59.37M | +377.4% | 4 |
| Next year | -8.37 | -9.87 – -7.59 | -10.99 | +23.8% | 176.42M | +197.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2023 | Piper Sandler | Downgrade | Overweight | Neutral |
| Oct 8, 2023 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Oct 8, 2023 | Jefferies | Downgrade | Buy | Hold |
| Oct 8, 2023 | Scotiabank | Upgrade | Sector Underperform | Sector Perform |
| Oct 8, 2023 | B. Riley Securities | Downgrade | Buy | Neutral |
| Oct 5, 2023 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Oct 5, 2023 | BMO Capital | Maintained | Market Perform | Market Perform |
| Oct 5, 2023 | Stifel | Reiterated | Buy | Buy |
| Sep 27, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Aug 9, 2023 | Citigroup | Upgrade | Neutral | Buy |
| Aug 8, 2023 | B. Riley Securities | Upgrade | Neutral | Buy |
| Aug 8, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 8, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 8, 2023 | BMO Capital | Maintained | Market Perform | Market Perform |
| Jul 26, 2023 | Scotiabank | Initiated | — | Sector Underperform |
| Jul 23, 2023 | Barclays | Maintained | Overweight | Overweight |
| Jul 23, 2023 | B. Riley Securities | Maintained | Neutral | Neutral |
| Jul 23, 2023 | Guggenheim | Maintained | Buy | Buy |
| Jul 13, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jun 15, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 24, 2023 | Barclays | Maintained | Overweight | Overweight |
| May 24, 2023 | BMO Capital | Maintained | Market Perform | Market Perform |
| May 10, 2023 | Citigroup | Maintained | Neutral | Neutral |
| May 10, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 10, 2023 | Oppenheimer | Reiterated | Perform | Perform |
| Apr 26, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Feb 28, 2023 | BMO Capital | Maintained | — | Market Perform |
| Jan 26, 2023 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jan 22, 2023 | B. Riley Securities | Maintained | — | Neutral |
| Dec 13, 2022 | SVB Leerink | Maintained | — | Outperform |